INTRODUCTION
The glycogen synthase kinase-3 (GSK-3) family of protein-serine kinases was initially characterized as a regulator of glycogen metabolism [1, 2] . The protein kinase phosphorylates residues on glycogen synthase, the rate-limiting enzyme ofglycogen synthesis, that are specifically dephosphorylated in response to insulin [3] . In mammals, two genes encode closely related proteins termed GSK-3a and ft [4] . The kinase is highly conserved and homologues have been cloned from plants, yeasts and mould [1] . The Drosophila homologue is a homeotic gene termed zeste-white3 or shaggy, suggesting the kinase has roles in a number of signal transduction pathways regulating cell growth, differentiation and development [5, 6] . phosphorylates the product of the mammalian protooncogene c-jun, a component of the activator protein-I (AP-1) transcription factor, at sites proximal to its DNA-binding domain, reducing DNA-binding-affinity [7] . Furthermore, GSK-3 inhibits transactivation of AP-I-responsive reporter genes implying that interaction between GSK-3 and cjun occurs in vivo [8, 9] .
Previous work has demonstrated GSK-3 to be active in resting cells. The enzyme is phosphorylated on tyrosine in vivo and this phosphorylation is required for activity [10] . Recent studies have demonstrated that GSK-3a and are phosphorylated and inhibited by two growth factor-stimulated protein kinases in vitro [11, 12] . In this report, we present evidence for the existence of such regulation of GSK-3/. in intact cells.
MATERIALS AND METHODS
All reagents were purchased from Sigma Chemical Co. (Mississauga, Ontario, Canada) unless indicated otherwise.
DNA constructs Serine 9 of human GSK-3, was mutated to alanine using the pAlter-l method (Promega, Madison, WI, U.S.A.). This wild expressing GSK-3,t or a mutant containing alanine at residue 9, we demonstrate that serine 9 is modified in intact cells and is targeted specifically by p9Orsk-1, and that phosphorylation leads to loss of activity. Since p90rsk-I is directly activated by mitogenactivated protein kinases, agonists of this pathway, such as insulin, repress GSK-3 function.
type and mutant GSK-3/1 were C-terminally tagged with the haemagglutinin (HA) epitope, YPYDVPDYASLGGPN, recognized by monoclonal antibody 12CA5 [13] and subcloned into pTMl [14] . N-terminally HA-tagged p90rsk-l kinase and human p70 S6 kinase were similarly engineered into pTMl. 5 mM EDTA, 50 mM NaF, 100 mM Na3VO4, 1 mM benzamidine and 5 mg/ml aprotinin. Proteins were immunoprecipitated by incubation with the monoclonal antibody 12CA5 (a gift from Joe Avruch, Harvard Medical School), which is reactive with the epitope tag, for 1 h at 4°C with subsequent precipitation with protein A-Sepharose and extensive washing in lysis buffer. Immunoprecipitation of proteins for the kinase assay was performed following the same protocol except that instead of RIPA, Gentle-Soft buffer [17] containing 5 mM EDTA, 50 mM NaF, 100 mM Na3VO4, 1 mM benzamidine and 5 mg/ml aprotinin was used.
Tryptic phosphopeptide analysis
Tryptic phosphopeptide analysis was performed according to Boyle et al. [18] . Radioactively labelled proteins were immunoprecipitated, resolved by 12.50% SDS/PAGE, transferred to PVDF membrane and visualized by autoradiography (Kodak XAR). The bands were excised, soaked in 0.5 % PVP-360 in 100 mM acetic acid for 30 min at 37°C, washed, and incubated overnight with 10 mg of 1-tosylamido-2-phenethyl chloromethyl ketone (TPCK)-trypsin (Worthington Biochemical Corp., Bedford, MA, U.S.A.) in 50 mM ammonium bicarbonate. The liquid phase was lyophilized, oxidized with performic acid and subsequently lyophilized three times with water. The samples were solubilized in pH 1.9 buffer, applied to thin-layer cellulose plates (BDH, Toronto, Ontario, Canada), separated by electrophoresis in pH 1.9 buffer for 30 min at 1OQ0 V in the first dimension, followed by ascending chromatography in the second dimension. Phosphopeptides were visualized by autoradiography with intensifying screens for 3-7 days.
Kinase assay
The kinase activity of immunoprecipitated GSK-3,8 proteins was tested by their ability to phosphorylate phospho-GSI peptide [19] . Phospho-GSl is a synthetic 25 amino acid peptide YRRA-AVPPSPSLSRHSSPHQSEDEE, derived from glycogen synthase and prephosphorylated by casein kinase II at serine 20 (underlined) and purified by reverse-phase h.p.l.c., creating three consensus sites for GSK-3-specific phosphorylation (bold). GSK- at serine 9 in vitro [11] , enhanced this effect, particularly following stimulation with phorbol 12-myristate 13-acetate (PMA) ( Figure  Ib) . In contrast, cotransfection ofp70 S6 kinase had no detectable effect on GSK-3/J phosphorylation (data not shown, see below)
but, when purified, was able to phosphorylate GSK-3,8 in vitro in agreement with Sutherland et al. [11] . These observations, albeit using overexpressed proteins, indicated that the mutation of a single residue (serine 9 to alanine) induces significant changes in GSK-3, phosphorylation within cells and implied a possible role for p90rsk-l in this event. Although p70 S6 kinase targeted serine 9 in vitro, this interaction was not observed in intact cells.
GSK-3fp is phosphorylated at serine 9 in vivo GSK-3,l proteins from radiolabelled cells coexpressing either GSK-3/i? or GSK-3,/A9 with p90rsk-1 ( Figure Ib To determine whether these phosphopeptide changes were due to the absence of serine 9 phosphorylation, a tryptic phosphopeptide map was prepared from purified baculovirus-expressed GSK-3# phosphorylated by p90rsk-1 in vitro (Figure 2e ). Phosphoamino-acid analysis of this preparation revealed phosphoserine (not shown), consistent with the reported exclusive serine 9 phosphorylation of GSK-3, by p90rsk-1 [5] . The in vitro phosphopeptide map contains three spots (Figure 2e , peptides la, 2a and 2b), two of which correspond to the spots missing in the map of the immunoprecipitated mutant (Figure 2c ). Mixing the peptides phosphorylated in vitro with those from immunoprecipitated GSK-3flA9 reconstituted the wild-type phospho- In support of this, both 2a and 2b are absent from GSK-bA9. Peptides la, lb and Ic are probably all derived from the region encompassing phosphotyrosine 216 of GSK-3,f, since the equivalent peptides are absent from a tryptic map of a tyrosine phosphorylation-site mutant of the fission yeast GSK-3 homologue (S. Plyte, J. R. Woodgett, J. D. Burke and K. Gould, unpublished work). Together, these results indicate that GSK-3, is phosphorylated at serine 9 in cells.
The effect of serine 9 phosphorylation of GSK-3 in vivo is inhibitory To assess the effect of serine 9 phosphorylation on GSK-3/3
activity, immunoprecipitated GSK-3,f and GSK-3,8A9 were assayed using a GSK-3-specific peptide substrate [19] . Immunoprecipitated GSK-3,/ consistently exhibited lower activity towards the phospho-GSI peptide substrate than immunoprecipitated GSK-3,fA9 ( Figure 3) . Furthermore, when coexpressed with p90rsk-1 in cells stimulated with PMA, the immunoprecipitated GSK-3, exhibited a further 2-3-fold decrease in activity towards the phospho-GSI peptide compared with the GSK-3f expressed alone (Figure 3) . In contrast, the activity of the mutant GSK-3/JA9 was unchanged upon coexpression with p90rsk-1 ( Figure 3) . These results confirm that p90rsk-1 plays an active role in serine 9 phosphorylation and is a likely candidate for direct regulation of GSK-3.
Coexpression of p70 S6 kinase with GSK-3fl and GSK-3,fA9
had no detectable effect on activity (data not shown), implying that even though p70 S6 kinase is able to phosphorylate GSK-3fl on serine 9 in vitro, such interaction does not occur in vivo. In addition, treatment of cells with the immunosuppressant macrolide, rapamycin, which specifically inhibits activation of p70 S6 kinase [21] , had no effect on the phosphorylation of peptides 2a and 2b (not shown). [23] .
DISCUSSION
Likewise, phorbol esters cause dephosphorylation of c-jun at sites which inhibit DNA binding and which are targeted by GSK-3 in vitro [7] . Phorbol esters also cause inhibition of GSK-3 in U937 cells (K. Hughes and J. R. Woodgett, unpublished observation). These observations suggested that GSK-3 may be subject to negative regulation (see Fig. 4 serine in GSK-3acis also inhibitory [12] , suggesting a common mechanism of inactivation of GSK-3 family members, including the Drosophila Shaggy proteins. The finding that p9Orsk-I is capable of inhibiting GSK-3 in cells implicates regulation via the ras/mitogen-activated protein (MAP) kinase signalling-pathway since p9Orsk-1 is itself regulated by phosphorylation by p42/p44 MAP kinases [24] . Rsk-1 inhibition of GSK-3 may be the major mechanism via which insulin stimulates glycogen deposition in skeletal muscle. If so, abnormal control of GSK-3 may contribute to the pathology of diabetes.
Genetic epistasis experiments in Drosophila have placed the GSK-3 homologue, Shaggy, downstream of the Wingless and Notch signalling pathways [25, 26] . Preliminary results suggest that the GSK-3 activity is inhibited in cells expressing mammalian Wnt proteins (K. Hughes, T. Dale and J. R. Woodgett unpublished observation). It will be of interest to determine whether these signalling pathways utilize a similar mechanism in regulating GSK-3.
